Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy
NCT ID: NCT05973734
Last Updated: 2023-08-21
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE1
Total Enrollment
24 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-10-01
Study Completion Date
2028-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical trial is to learn if patients who have brittle type 1 diabetes receiving an islet transplantation will have better control of their sugars if they also receive one of 2 types of immune cells along with the islet transplant. The participants will receive either their own immune cells, called regulatory T cells, or immune cells from the bone marrow of the islet donor.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus
NCT00315614
Type 1 Diabetes Mellitus
TERMINATED
PHASE2
Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen
NCT00021801
Type 1 Diabetes Mellitus
COMPLETED
PHASE2
Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation
NCT00286624
Type 1 Diabetes Mellitus
Hypoglycemia
COMPLETED
PHASE1/PHASE2
Islet Transplantation in Patients With "Brittle" Type I Diabetes
NCT01630850
Diabetes Mellitus, Type 1
RECRUITING
NA
Islet Cell Transplants for Diabetes
NCT00303134
Diabetes Mellitus, Type 1
TERMINATED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Islet transplantation success remains limited by the immediate loss of islet after transplantation, rejection, and side effect from immunosuppression. Preclinical animal models provide evidence that donor bone marrow cells OR regulatory T cells infused at the time of islet transplantation can improve the survival of islets after transplantation and reduce the need for immunosuppression. The purpose of this study is to evaluate the feasibility and safety of combining an islet transplant with the recipient's Tregs OR deceased donor bone marrow cells in patients with brittle type 1 diabetes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Islet Transplantation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
All patients are planned to receive an islet transplantation. The patients will also receive either Arm 1) recipient T regulatory cell infusion or arm 2) same donor vertebral body derived bone marrow cell infusion. Attribution to either arm will be based on the availability of either cell product in specific cases.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Recipient T Regulatory Cell
T regulatory cells prior to islet transplantation, induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF).
Group Type
EXPERIMENTAL
Infusion of recipient T regulatory cell
Intervention Type
BIOLOGICAL
Patients will undergo a single apheresis collection with a target total blood volume of 20-30 L and the collected cells used as the source of purified Tregs to be infused following the islet transplantation. In the event a patient is unable to meet the collection target, a second collection may be performed.
Donor Derived Vertebral Bone Marrow
Deceased donor vertebral bone marrow (VBM) cells, induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF).
Group Type
EXPERIMENTAL
Infusion of concomitant Donor Derived Vertebral Bone Marrow
Intervention Type
BIOLOGICAL
The cells from the donor VB and spleen are processed under cGMP conditions and released for infusion after the respective recipient has undergone transplant and conditioning. Under this protocol, the donor's VB will be obtained at the same time as the pancreatic islets and will be the source of HSC for infusion with the intent to establish immune tolerance to the donor's pancreatic islet cells. Subjects will receive one infusion of allogeneic cadaveric islets. Subjects will receive induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF). After islet transplantation, the VBM cells will be infused in one time window: on day 0-1. Subjects will undergo closed-loop insulin pump glucose control peri-transplant.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Infusion of recipient T regulatory cell
Patients will undergo a single apheresis collection with a target total blood volume of 20-30 L and the collected cells used as the source of purified Tregs to be infused following the islet transplantation. In the event a patient is unable to meet the collection target, a second collection may be performed.
Intervention Type
BIOLOGICAL
Infusion of concomitant Donor Derived Vertebral Bone Marrow
The cells from the donor VB and spleen are processed under cGMP conditions and released for infusion after the respective recipient has undergone transplant and conditioning. Under this protocol, the donor's VB will be obtained at the same time as the pancreatic islets and will be the source of HSC for infusion with the intent to establish immune tolerance to the donor's pancreatic islet cells. Subjects will receive one infusion of allogeneic cadaveric islets. Subjects will receive induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF). After islet transplantation, the VBM cells will be infused in one time window: on day 0-1. Subjects will undergo closed-loop insulin pump glucose control peri-transplant.
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female patients age 18 to 70 years of age.
* Ability to provide written informed consent.
* Mentally stable and able to comply with the procedures of the study protocol.
* Clinical history compatible with T1D with onset of disease at \< 45 years of age, insulin- dependence for ≥ 5 years at the time of enrollment, or a sum of patient age and insulin dependent diabetes duration of ≥ 28.
* Absence of stimulated C peptide (\< 0.3 ng/mL) in response to a mixed meal tolerance test measured at 60 and 90 minutes after the start of consumption
* Involvement in intensive diabetes management defined as self-monitoring of glucose values no less than a mean of three times each day averaged over each week and by the administration of three or more insulin injections each day or insulin pump therapy. Such management must be under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least 3 clinical evaluations during the 12 months prior to study enrollment.
* At least two episodes of severe hypoglycemia in the 12 months prior to study enrollment.
* Reduced awareness of hypoglycemia as defined by a Clarke score of 4 or more OR a HYPO score greater than or equal to the 90th percentile (1047) during the screening period and within the last 6 months prior to randomization.
* Women of childbearing potential may be enrolled if a pregnancy test is negative, and they agree to the use of 2 forms of contraception from Screening to the end of the study. Males must agree to use 2 forms of contraception from Screening to the end of the study if their partners are of childbearing potential.
* Acceptable methods of birth control which must be used together are:
* Oral contraceptive and condom (combination oral contraceptives containing the second- generation progestin (levonorgestrel) and \<30 μg of estrogen should be utilized),
* IUD and condom,
* Diaphragm with spermicide and condom
* Subject must complete training on how to use the Tandem X2 pump with Control IQ technology by a certified Diabetes Educator or physician. Patients must complete at least 2 hour training to the satisfaction of the educator and show proficiency and understanding in its use as judged by the educator.
* Patients with prior kidney transplantation on immunosuppressive medications are eligible provided they meet all eligibility criteria above excluding the need for hypoglycemia unawareness. Patients should not be candidates for solid organ pancreas transplant or have declined the surgical option.
* Ability to provide written informed consent.
* Mentally stable and able to comply with the procedures of the study protocol.
* Clinical history compatible with T1D with onset of disease at \< 45 years of age, insulin- dependence for ≥ 5 years at the time of enrollment, or a sum of patient age and insulin dependent diabetes duration of ≥ 28.
* Absence of stimulated C peptide (\< 0.3 ng/mL) in response to a mixed meal tolerance test measured at 60 and 90 minutes after the start of consumption
* Involvement in intensive diabetes management defined as self-monitoring of glucose values no less than a mean of three times each day averaged over each week and by the administration of three or more insulin injections each day or insulin pump therapy. Such management must be under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least 3 clinical evaluations during the 12 months prior to study enrollment.
* At least two episodes of severe hypoglycemia in the 12 months prior to study enrollment.
* Reduced awareness of hypoglycemia as defined by a Clarke score of 4 or more OR a HYPO score greater than or equal to the 90th percentile (1047) during the screening period and within the last 6 months prior to randomization.
* Women of childbearing potential may be enrolled if a pregnancy test is negative, and they agree to the use of 2 forms of contraception from Screening to the end of the study. Males must agree to use 2 forms of contraception from Screening to the end of the study if their partners are of childbearing potential.
* Acceptable methods of birth control which must be used together are:
* Oral contraceptive and condom (combination oral contraceptives containing the second- generation progestin (levonorgestrel) and \<30 μg of estrogen should be utilized),
* IUD and condom,
* Diaphragm with spermicide and condom
* Subject must complete training on how to use the Tandem X2 pump with Control IQ technology by a certified Diabetes Educator or physician. Patients must complete at least 2 hour training to the satisfaction of the educator and show proficiency and understanding in its use as judged by the educator.
* Patients with prior kidney transplantation on immunosuppressive medications are eligible provided they meet all eligibility criteria above excluding the need for hypoglycemia unawareness. Patients should not be candidates for solid organ pancreas transplant or have declined the surgical option.
Exclusion Criteria
* Body mass index (BMI) \>30 kg/m2 or patient weight ≤50kg.
* Insulin requirement of \>1.0 IU/kg/day or \<15 U/day. 3. HbA1c \>10%.
* Treatment with any anti-diabetic medication other than insulin within 4 weeks of Screening
* Untreated proliferative diabetic retinopathy.
* Blood Pressure: SBP \>180 mmHg or DBP \>100 mmHg on optimal treatment.
* Estimated glomerular filtration rate of \<50 mL/min/1.73m2.
* Presence or history of macroalbuminuria (\>500mg/g creatinine).
* Presence or history of panel-reactive anti-HLA antibodies \>50%. Negative cross- match by flow cytometry and no DSA to organ donor by standard methods.
* For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male participants: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception
* Presence of active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB). Subjects with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection.
* Negative screen for Epstein-Barr Virus (EBV) by IgG determination.
* Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection within one year prior to study enrollment.
* Any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin.
* Known active alcohol or substance abuse.
* Baseline Hb below the lower limits of normal; neutropenia (\<1,500/7L), or thrombocytopenia (platelets \<100,000/7L).
* Any coagulopathy or medical condition requiring long-term anticoagulant therapy (e.g., warfarin) after islet transplantation (low-dose aspirin treatment is allowed) or patients with an international normalized ratio (INR) \>1.5.
* Severe co-existing cardiac disease, characterized by any one of these conditions:
* recent myocardial infarction (within past 6 months).
* evidence of uncorrectable ischemia on functional cardiac exam within the last year.
* left ventricular ejection fraction \<30%.
* Persistent elevation of liver function tests at the time of study entry. Persistent serum glutamic-oxaloacetic transaminase (SGOT \[AST\]), serum glutamate pyruvate transaminase (SGPT \[ALT\]), or total bilirubin, with values \> 1.5 times normal upper limits will exclude a patient.
* Acute or chronic pancreatitis.
* Treatment with any anti-diabetic medication other than insulin within 4 weeks of enrollment.
* Use of any investigational agents within 4 or more weeks of enrollment, depending upon the pharmacokinetics of the investigational agent and durability of changes with treatment in immune function or glycemic regulation.
* Administration of live attenuated vaccine(s) within 2 months of enrollment.
* Any medical condition that, in the opinion of the investigator, will interfere with safe participation in the trial.
* A previous islet transplant.
* History of medical non-adherence or poor social support.
* Individuals with selective IgA deficiencies (IgA level less than 15 mg/dL) who have known antibody against IgA.
* Insulin requirement of \>1.0 IU/kg/day or \<15 U/day. 3. HbA1c \>10%.
* Treatment with any anti-diabetic medication other than insulin within 4 weeks of Screening
* Untreated proliferative diabetic retinopathy.
* Blood Pressure: SBP \>180 mmHg or DBP \>100 mmHg on optimal treatment.
* Estimated glomerular filtration rate of \<50 mL/min/1.73m2.
* Presence or history of macroalbuminuria (\>500mg/g creatinine).
* Presence or history of panel-reactive anti-HLA antibodies \>50%. Negative cross- match by flow cytometry and no DSA to organ donor by standard methods.
* For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male participants: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception
* Presence of active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB). Subjects with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection.
* Negative screen for Epstein-Barr Virus (EBV) by IgG determination.
* Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection within one year prior to study enrollment.
* Any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin.
* Known active alcohol or substance abuse.
* Baseline Hb below the lower limits of normal; neutropenia (\<1,500/7L), or thrombocytopenia (platelets \<100,000/7L).
* Any coagulopathy or medical condition requiring long-term anticoagulant therapy (e.g., warfarin) after islet transplantation (low-dose aspirin treatment is allowed) or patients with an international normalized ratio (INR) \>1.5.
* Severe co-existing cardiac disease, characterized by any one of these conditions:
* recent myocardial infarction (within past 6 months).
* evidence of uncorrectable ischemia on functional cardiac exam within the last year.
* left ventricular ejection fraction \<30%.
* Persistent elevation of liver function tests at the time of study entry. Persistent serum glutamic-oxaloacetic transaminase (SGOT \[AST\]), serum glutamate pyruvate transaminase (SGPT \[ALT\]), or total bilirubin, with values \> 1.5 times normal upper limits will exclude a patient.
* Acute or chronic pancreatitis.
* Treatment with any anti-diabetic medication other than insulin within 4 weeks of enrollment.
* Use of any investigational agents within 4 or more weeks of enrollment, depending upon the pharmacokinetics of the investigational agent and durability of changes with treatment in immune function or glycemic regulation.
* Administration of live attenuated vaccine(s) within 2 months of enrollment.
* Any medical condition that, in the opinion of the investigator, will interfere with safe participation in the trial.
* A previous islet transplant.
* History of medical non-adherence or poor social support.
* Individuals with selective IgA deficiencies (IgA level less than 15 mg/dL) who have known antibody against IgA.
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Francisco
OTHER
Sponsor Role
collaborator
Stanford University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stephan Busque
Protocol Director
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephan Busque, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University
Palo Alto, California, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Stephan Busque, MD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, Shapiro AM, Vantyghem MC. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004 Apr;53(4):955-62. doi: 10.2337/diabetes.53.4.955.
Reference Type
BACKGROUND
Kessler L, Passemard R, Oberholzer J, Benhamou PY, Bucher P, Toso C, Meyer P, Penfornis A, Badet L, Wolf P, Colin C, Morel P, Pinget M; GRAGIL Group. Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation: interest of continuous glucose monitoring. Diabetes Care. 2002 Dec;25(12):2256-62. doi: 10.2337/diacare.25.12.2256.
Reference Type
BACKGROUND
Streja D. Can continuous glucose monitoring provide objective documentation of hypoglycemia unawareness? Endocr Pract. 2005 Mar-Apr;11(2):83-90. doi: 10.4158/EP.11.2.83.
Reference Type
BACKGROUND
Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86. doi: 10.1056/NEJM199309303291401.
Reference Type
BACKGROUND
Hirsch IB. Insulin analogues. N Engl J Med. 2005 Jan 13;352(2):174-83. doi: 10.1056/NEJMra040832. No abstract available.
Reference Type
BACKGROUND
Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003 Jun;26(6):1902-12. doi: 10.2337/diacare.26.6.1902.
Reference Type
BACKGROUND
Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994 Jul;17(7):697-703. doi: 10.2337/diacare.17.7.697.
Reference Type
BACKGROUND
Larsen JL. Pancreas transplantation: indications and consequences. Endocr Rev. 2004 Dec;25(6):919-46. doi: 10.1210/er.2002-0036.
Reference Type
BACKGROUND
Cryer PE, Fisher JN, Shamoon H. Hypoglycemia. Diabetes Care. 1994 Jul;17(7):734-55. doi: 10.2337/diacare.17.7.734. No abstract available.
Reference Type
BACKGROUND
Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM. Five-year follow-up after clinical islet transplantation. Diabetes. 2005 Jul;54(7):2060-9. doi: 10.2337/diabetes.54.7.2060.
Reference Type
BACKGROUND
Hering BJ, Clarke WR, Bridges ND, Eggerman TL, Alejandro R, Bellin MD, Chaloner K, Czarniecki CW, Goldstein JS, Hunsicker LG, Kaufman DB, Korsgren O, Larsen CP, Luo X, Markmann JF, Naji A, Oberholzer J, Posselt AM, Rickels MR, Ricordi C, Robien MA, Senior PA, Shapiro AM, Stock PG, Turgeon NA; Clinical Islet Transplantation Consortium. Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care. 2016 Jul;39(7):1230-40. doi: 10.2337/dc15-1988. Epub 2016 Apr 18.
Reference Type
BACKGROUND
Krzystyniak A, Golab K, Witkowski P, Trzonkowski P. Islet cell transplant and the incorporation of Tregs. Curr Opin Organ Transplant. 2014 Dec;19(6):610-5. doi: 10.1097/MOT.0000000000000130.
Reference Type
BACKGROUND
Pierini A, Iliopoulou BP, Peiris H, Perez-Cruz M, Baker J, Hsu K, Gu X, Zheng PP, Erkers T, Tang SW, Strober W, Alvarez M, Ring A, Velardi A, Negrin RS, Kim SK, Meyer EH. T cells expressing chimeric antigen receptor promote immune tolerance. JCI Insight. 2017 Oct 19;2(20):e92865. doi: 10.1172/jci.insight.92865.
Reference Type
BACKGROUND
Cryer PE. Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes. 1994 Nov;43(11):1378-89. doi: 10.2337/diab.43.11.1378.
Reference Type
BACKGROUND
Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000 Jul 27;343(4):230-8. doi: 10.1056/NEJM200007273430401.
Reference Type
BACKGROUND
Markmann JF, Deng S, Huang X, Desai NM, Velidedeoglu EH, Lui C, Frank A, Markmann E, Palanjian M, Brayman K, Wolf B, Bell E, Vitamaniuk M, Doliba N, Matschinsky F, Barker CF, Naji A. Insulin independence following isolated islet transplantation and single islet infusions. Ann Surg. 2003 Jun;237(6):741-9; discussion 749-50. doi: 10.1097/01.SLA.0000072110.93780.52.
Reference Type
BACKGROUND
Meyer EH, Laport G, Xie BJ, MacDonald K, Heydari K, Sahaf B, Tang SW, Baker J, Armstrong R, Tate K, Tadisco C, Arai S, Johnston L, Lowsky R, Muffly L, Rezvani AR, Shizuru J, Weng WK, Sheehan K, Miklos D, Negrin RS. Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight. 2019 May 16;4(10):e127244. doi: 10.1172/jci.insight.127244. eCollection 2019 May 16.
Reference Type
BACKGROUND
Huber BC, Ransohoff JD, Ransohoff KJ, Riegler J, Ebert A, Kodo K, Gong Y, Sanchez-Freire V, Dey D, Kooreman NG, Diecke S, Zhang WY, Odegaard J, Hu S, Gold JD, Robbins RC, Wu JC. Costimulation-adhesion blockade is superior to cyclosporine A and prednisone immunosuppressive therapy for preventing rejection of differentiated human embryonic stem cells following transplantation. Stem Cells. 2013 Nov;31(11):2354-63. doi: 10.1002/stem.1501.
Reference Type
BACKGROUND
Bellacen K, Kalay N, Ozeri E, Shahaf G, Lewis EC. Revascularization of pancreatic islet allografts is enhanced by alpha-1-antitrypsin under anti-inflammatory conditions. Cell Transplant. 2013;22(11):2119-33. doi: 10.3727/096368912X657701. Epub 2012 Oct 8.
Reference Type
BACKGROUND
Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA. 1988 Sep 2;260(9):1259-64.
Reference Type
BACKGROUND
Baranovski BM, Ozeri E, Shahaf G, Ochayon DE, Schuster R, Bahar N, Kalay N, Cal P, Mizrahi MI, Nisim O, Strauss P, Schenker E, Lewis EC. Exploration of alpha1-antitrypsin treatment protocol for islet transplantation: dosing plan and route of administration. J Pharmacol Exp Ther. 2016 Dec;359(3):482-490. doi: 10.1124/jpet.116.236067. Epub 2016 Nov 7.
Reference Type
BACKGROUND
Weir GC, Ehlers MR, Harris KM, Kanaparthi S, Long A, Phippard D, Weiner LJ, Jepson B, McNamara JG, Koulmanda M, Strom TB; ITN RETAIN Study Team. Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics. Pediatr Diabetes. 2018 Aug;19(5):945-954. doi: 10.1111/pedi.12660. Epub 2018 May 7.
Reference Type
BACKGROUND
Koulmanda M, Bhasin M, Fan Z, Hanidziar D, Goel N, Putheti P, Movahedi B, Libermann TA, Strom TB. Alpha 1-antitrypsin reduces inflammation and enhances mouse pancreatic islet transplant survival. Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15443-8. doi: 10.1073/pnas.1018366109. Epub 2012 Sep 4.
Reference Type
BACKGROUND
Wang J, Sun Z, Gou W, Adams DB, Cui W, Morgan KA, Strange C, Wang H. alpha-1 Antitrypsin Enhances Islet Engraftment by Suppression of Instant Blood-Mediated Inflammatory Reaction. Diabetes. 2017 Apr;66(4):970-980. doi: 10.2337/db16-1036. Epub 2017 Jan 9.
Reference Type
BACKGROUND
Berger M, Liu M, Uknis ME, Koulmanda M. Alpha-1-antitrypsin in cell and organ transplantation. Am J Transplant. 2018 Jul;18(7):1589-1595. doi: 10.1111/ajt.14756. Epub 2018 Apr 24.
Reference Type
BACKGROUND
Taylor GD, Kirkland T, Lakey J, Rajotte R, Warnock GL. Bacteremia due to transplantation of contaminated cryopreserved pancreatic islets. Cell Transplant. 1994 Jan-Feb;3(1):103-6. doi: 10.1177/096368979400300114.
Reference Type
BACKGROUND
Lloveras J, Farney AC, Sutherland DE, Wahoff D, Field J, Gores PF. Significance of contaminated islet preparations in clinical islet transplantation. Transplant Proc. 1994 Apr;26(2):579-80. No abstract available.
Reference Type
BACKGROUND
Rickels MR, Kamoun M, Kearns J, Markmann JF, Naji A. Evidence for allograft rejection in an islet transplant recipient and effect on beta-cell secretory capacity. J Clin Endocrinol Metab. 2007 Jul;92(7):2410-4. doi: 10.1210/jc.2007-0172. Epub 2007 May 8.
Reference Type
BACKGROUND
Rickels MR, Kearns J, Markmann E, Palanjian M, Markmann JF, Naji A, Kamoun M. HLA sensitization in islet transplantation. Clin Transpl. 2006:413-20.
Reference Type
BACKGROUND
Olack BJ, Swanson CJ, Flavin KS, Phelan D, Brennan DC, White NH, Lacy PE, Scharp DW, Poindexter N, Mohanakumar T. Sensitization to HLA antigens in islet recipients with failing transplants. Transplant Proc. 1997 Jun;29(4):2268-9. doi: 10.1016/s0041-1345(97)00327-8. No abstract available.
Reference Type
BACKGROUND
Mao Q, Terasaki PI, Cai J, Briley K, Catrou P, Haisch C, Rebellato L. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant. 2007 Apr;7(4):864-71. doi: 10.1111/j.1600-6143.2006.01711.x.
Reference Type
BACKGROUND
Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant. 2004 Mar;4(3):438-43. doi: 10.1111/j.1600-6143.2004.00360.x.
Reference Type
BACKGROUND
Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant. 2007 Feb;7(2):408-15. doi: 10.1111/j.1600-6143.2006.01644.x. Epub 2007 Jan 4.
Reference Type
BACKGROUND
Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med. 1991 Apr;90(4):450-9.
Reference Type
BACKGROUND
Ramsay RC, Goetz FC, Sutherland DE, Mauer SM, Robison LL, Cantrill HL, Knobloch WH, Najarian JS. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med. 1988 Jan 28;318(4):208-14. doi: 10.1056/NEJM198801283180403.
Reference Type
BACKGROUND
Hirshberg B, Rother KI, Digon BJ 3rd, Lee J, Gaglia JL, Hines K, Read EJ, Chang R, Wood BJ, Harlan DM. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care. 2003 Dec;26(12):3288-95. doi: 10.2337/diacare.26.12.3288.
Reference Type
BACKGROUND
Ryan EA, Lakey JR, Paty BW, Imes S, Korbutt GS, Kneteman NM, Bigam D, Rajotte RV, Shapiro AM. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes. 2002 Jul;51(7):2148-57. doi: 10.2337/diabetes.51.7.2148.
Reference Type
BACKGROUND
Ryan EA, Paty BW, Senior PA, Shapiro AM. Risks and side effects of islet transplantation. Curr Diab Rep. 2004 Aug;4(4):304-9. doi: 10.1007/s11892-004-0083-8.
Reference Type
BACKGROUND
Froud T, Yrizarry JM, Alejandro R, Ricordi C. Use of D-STAT to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant. 2004;13(1):55-9. doi: 10.3727/000000004772664897.
Reference Type
BACKGROUND
Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, Matsumoto I, Ihm SH, Zhang HJ, Parkey J, Hunter DW, Sutherland DE. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005 Feb 16;293(7):830-5. doi: 10.1001/jama.293.7.830.
Reference Type
BACKGROUND
Manciu N, Beebe DS, Tran P, Gruessner R, Sutherland DE, Belani KG. Total pancreatectomy with islet cell autotransplantation: anesthetic implications. J Clin Anesth. 1999 Nov;11(7):576-82. doi: 10.1016/s0952-8180(99)00100-2.
Reference Type
BACKGROUND
Froberg MK, Leone JP, Jessurun J, Sutherland DE. Fatal disseminated intravascular coagulation after autologous islet transplantation. Hum Pathol. 1997 Nov;28(11):1295-8. doi: 10.1016/s0046-8177(97)90204-5.
Reference Type
BACKGROUND
Mehigan DG, Bell WR, Zuidema GD, Eggleston JC, Cameron JL. Disseminated intravascular coagulation and portal hypertension following pancreatic islet autotransplantation. Ann Surg. 1980 Mar;191(3):287-93. doi: 10.1097/00000658-198003000-00006.
Reference Type
BACKGROUND
Mittal VK, Toledo-Pereyra LH, Sharma M, Ramaswamy K, Puri VK, Cortez JA, Gordon D. Acute portal hypertension and disseminated intravascular coagulation following pancreatic islet autotransplantation after subtotal pancreatectomy. Transplantation. 1981 Apr;31(4):302-4. No abstract available.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
58350
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes
NCT03746769
RECRUITING
PHASE1/PHASE2
Islet Cell Transplant for Type 1 Diabetes
NCT01909245
ACTIVE_NOT_RECRUITING
PHASE2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
NCT01241864
RECRUITING
PHASE2
Islet Transplant for Type 1 or Surgical Diabetes
NCT01606475
NO_LONGER_AVAILABLE
Omental Islet Transplant
NCT02821026
COMPLETED
PHASE1/PHASE2
Pancreatic Islet Transplantation to the Anterior Chamber of the Eye
NCT04198350
WITHDRAWN
NA
Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment
NCT01148680
COMPLETED
PHASE3
B-Lymphocyte Immunotherapy in Islet Transplantation
NCT00468442
TERMINATED
PHASE2
Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes
NCT03977662
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes
NCT00708604
COMPLETED
PHASE1
Islet Transplantation in Type 1 Diabetic Patients
NCT00214253
COMPLETED
PHASE1
Islet Cell Transplantation Alone in Patients With Type I Diabetes Mellitus: Steroid-free Immunosuppression
NCT00021788
COMPLETED
PHASE2
Islet Allotransplantation for Type 1 Diabetic Patients
NCT03259256
UNKNOWN
PHASE3
Islet Transplantation for Type 1 Diabetes Mellitus
NCT00437398
TERMINATED
PHASE1/PHASE2
Islet Transplantation for Patients With Type 1 Diabetes
NCT00073281
COMPLETED
PHASE1
Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus
NCT00579371
TERMINATED
PHASE1/PHASE2
Islet Allotransplantation in Type 1 Diabetes
NCT01705899
SUSPENDED
PHASE1
Energy Balance Following Islet Transplantation
NCT03063229
TERMINATED
NA
Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes
NCT01974674
UNKNOWN
PHASE2
Bone Marrow vs Liver as Site for Islet Transplantation
NCT01722682
COMPLETED
PHASE1/PHASE2
Infusion of Autologous T Regulatory Cells (T Reg) at the Time of Transplantation of Allogenic Islets of Langerhans
NCT04820270
UNKNOWN
NA
Pancreatic Islet Cell Transplantation
NCT00214786
COMPLETED
PHASE1
Islet Transplantation in Type 1 Diabetes
NCT00434811
COMPLETED
PHASE3
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
NCT06305286
RECRUITING
PHASE1/PHASE2
Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen
NCT00706420
ACTIVE_NOT_RECRUITING
PHASE1